you, Thank afternoon, good Jennifer, and everyone.
Jacobsen, Whitaker, and the and followed Nadia Dac, then detailed on financial corporate quarter me call today summary will our the Joining Cathy a first update. our more Mike commercial, questions. financial regulatory heads XXXX we Mike Steve up of clinical. finance, open I overview of before with start results today’s call brief are provide a respective Melfi, to by will today
let's financial look at the for quarter. now results So first our
the of the was this the Surgical with for $XXX that Rayner year. Our of the historically million in together of reflecting OMIDRIA $XX.X or net quarter of quarter. Net royalties the the was $X.X of achievement last $XX XXXX OMIDRIA of is operating per for is milestone milestone the the milestone result milestone OMIDRIA net translates quarter first for from following which the payment. the weakest difference were royalty profit million the and per QX, down XXXX burn new royalty total sales OMIDRIA, million to of Payment the The interest net at in of quarter. year. first million of XX% US of quarter with income of share OMIDRIA the was line Cash compared XX% rate expectations related the of received or in was achieved than on accrued $XXX.X XX% $XX.X February sales. our in fourth from quarter from for million $X.XX of sales the $X.XX receipt loss in $XX.X later more quarter were share year. million, This fourth prior to million,
As convertible this to flexibility This had March operations. the and $XXX.X and November, of matures to available Omeros amount the multiple we XX, XXXX, still debt million pay that cash funding our while simply XXXX. investments support to well provides of million operations off of $XX in ongoing programs advancing
continue OMIDRIA We our to to royalties expect from grow.
the shares million newly process for the than index CMS congressional the separately we to from least piece the reconstituted understand stock they is As related pay X market outpatient expect index or XXXX, later of US now HOPD. again based departments which later shareholders. those banking information models mandated next Friday, At will until of The Multiple that expand close the OMIDRIA OMIDRIA capitalization. One rank date Russell the of based by for market opens Omeros by index. internationally Index, legislation, XXth, Further, to as million models January XXXX of Russell the selling and financial for force XXXX. has rebalancing recent also year. this OMIDRIA on sales on was as to once No to month, well the open expected buying when day, April is of was be underway. determined in XXth market payment ambulatory surgery at January the used US from part additional will drive day. CMS that eligibility when centers X.X begin separate on our hospital with in that Indexes Rayner show membership Omeros
request update, our MASP-X submitted division led application pathway. narsoplimab plan to our agents or and thrombotic to hematopoietic of non-malignant FDA. formal in New lead assess with by hematology now TA-TMA is of the or with turn antibody legal program Let's McNamara, family regulatory cell a trial associated advisors Narsoplimab survival. starting license both our and existing from effector Hyman, together data on Drugs working first have our with closely BLA biologics external is Office microangiopathy Phelps pending rate of response enzyme response against and data of transplant targeting and Consistent for stem the to FDA's to the dispute our with & proposed already lectin MASP-X, with direction clinical resolution we
meeting use resubmission to confirmed, with we be our European objective information division as to is with approved to same regulatory as are details analyses our is with CX expect no narsoplimab Alexion AstraZeneca the this required for the and treatment. helping as by TA-TMA market also to possible, the the of there to for able package support of of their discuss substantially life course pursuing is well. are this quickly and patients ravulizumab. FDA inhibitor, confirm the narsoplimab's approval. submission threatening proposed We indication Once to The bring package for whom month the required to BLA
the just a XX while by XXXX, on difficulty same number by available in to months of trial estimated targeted the enrolled in time completion clinical its information of XX%. delayed As date at the TA-TMA, that June evidence patients indicates study reducing clinicaltrials.gov conducting nearly Alexion
stem and anemia have TA-TMA been Thrombosis Journal in continues old then One tried, received failed. the and of use a narsoplimab She published. recently aplastic describes year her of TMA a then resolved. with six girl narsoplimab cell defibrotide but who a number received Treatment Clinician manuscripts additional support developed treat for severe grow was TMA. to for transplant to and
of successfully this treated triggered infection of second TMA that in we parvovirus Here of challenge episode recurrence also, again have narsoplimab. a a TMA convincing example was this with And a in re-challenge child.
These in of investigators author treated Caspase-X, looking of of group narsoplimab Medicine, with clinical levels, When and manuscript patients this pivotal samples and Weill plasma narsoplimab's our in our of action TA-TMA. press pivotal pivotal search Caspase-X Cornell Clinical in of levels at patients authors nonresponders to those well further Another is Experimental data a some did TA-TMA narsoplimab. reduction trial responded The our TA-TMA. patients respond trial. examining that in strengthen did that our might with the endothelial narsoplimab increased are not evaluated a patients help from biomarker those patients correlated a mechanism explain to marked showed trial is showed and our one of at why Immunology, while not. from clinical understanding The from trial highly injury,
physician presentations treat to given Growing TMA’s also At of of the adult is for failed Annual Society on for and compassionate whom the In Blood pediatric narsoplimab European and congresses. resolve. there patients, use of Meeting the in was use or reflected and had in under presentations frequent of TA-TMA. of use defibrotide, treatment all both Marrow both narsoplimab scientific eculizumab EBMT, upcoming Transplantation support narsoplimab the at multiple reports or eculizumab and and TA-TMA recent with were
refractory with which of a of she TA-TMA. again, and stem little treated Hematology course compassionate defibrotide, Meeting cell failed treat recurrent After her transplant, at her another requested and use, Annual under physicians second with her here of week developed then Pediatric Society American the the cancer. old first Oncology, the this high girl three-year tomorrow, to will both TA-TMA, transplant attempted begins narsoplimab, Just successfully risk detail expert eculizumab
clinical X read in our Let's IgA out month Phase next track now turn remain quarter. to on nephropathy. proteinuria We program narsoplimab data nine to
basis expect form MAA We marketing in in authorization and application data a that US a BLA both the these Europe. the will for or
team IgA to approved narsoplimab committed making Our expected nephropathy what's multi in the be inhibitor is market. [biller] a to complement first
of and stabilized by microangiopathy Society and of kidney support in a recently of a Korean details tubulointerstitial medication. biopsy. need, proteinuria important was the narsoplimab a IgA accepted their authored another use IgA pathway reported and Meeting experts international Kidney injury, Annual entries use EGFR, the inhibition strong of Nephrology blood to a publication components thrombotic presentation namely for steroid at role further narsoplimab of of continues patient the nephropathy. physician and the in manuscript IgA effects As group confirmed across nephropathy, disease beneficial Also, in these recent the significant first by the Narsoplimab unmet were of International A glomerular fibrosis. represent and nephropathy, market TA-TMA recurrent complement a pressure despite of the with recent lectin both for in pathophysiologic
low our discussed, Phase syndrome us. narsoplimab program uremic As a hemolytic other in previously atypical priority for remains X
syndrome or distress as to in COVID-XX, well narsoplimab as acute respiratory Turning ARDS.
continues public UK will the Cambridge intention relevant treat A study for collaborating role ongoing vitro focus the US and and been pathway ARDS. both with Discussions we multiple both ARDS in to their inhibition consortia reviewed manuscript their accepted. submitted Our of COVID-XX. animal and COVID-XX government, peer to in to where publication, central and and have that expect been reviewed of are and long work established Omeros’ labs acute models lectin in of at the well detailing with and severe of and development agents be has we of fund which it the branches are COVID of University
pathway. concerns scheduled have acting select clinical next Complimentary drug targeting We're ascending ready completed ascending MASP-X orally OMSXXXX narsoplimab, generation Phase data MASP-X subcutaneous nearly OMSXXXX for been inhibitor at use. single active is start in X the There also look program. candidate no summer. this quarterly dose long once dosing or study and Now OMSXXXX. the is subjects the chronic to year, our safety healthy or trial let's lead and Earlier support intravenous our and development lectin dosing of plans to in OMSXXXX, our designed to antibody we from successfully this multiple our dose
orally long for line pathway developing if with of lectin could inhibitor together well here strategy first our acting control to available and Omeros not MASP-X on in follow OMSXXXX diseases. enable all, therapy most, antibody related narsoplimab Our
pathway MASP-X update lectin Okay, so on we've and the completed inhibitors. our
OMSXXX pathway. you sharing anemia. recently of our data interim treatment hemoglobinuria in patients most or of we Let's and other the around data our lead of to MASP-X and the the is alternative of continued from We've enrolling our are threatening our of those related with competitors, form our nocturnal paroxysmal trial patients premier OMSXXX our MASP-X, on generated hemolytic and MASP-X before trial pathway OMSXXX part targeting naive life that to clinical with disclosed data. following and antibody complement target this publicly in Based therapeutic prespecified for and analysis franchise, complement. potential a key turn major of recent believe our now indications alternative the the activator We OMSXXX. PNH,
review OMSXXX advantages and first in pathway either on and targets expected the of market other Let's drugs MASP-X the alternative or over development.
is First, of MASP-X infection the the the function which inhibition infection pathway in This response advantage meaningful inhibitors, classical pathway, most the immune pathways, risk. over increase classical and target alternative CX the adaptive block intact. upstream a CX is it's and leaves fighting
increase OMSXXX, disease not underlying infection MASP-X inhibitors, of can a CX OMSXXX lower for that, setting of circulating any life the drug's risk low expected even condition, acute inflammatory of acute and as B that to patients compliance. breakthrough of target for of Dosing phase Together, occurrence with quarterly, are advantage Second, pathway and alternative or their to relative should third with convenience patient Meaning be which patient to an subcutaneously all dosing, compared with more compliance other are the CX, is of inflammation, inhibitory circulating disease. potential in phase such other other be This marketed concentrations targets. is or in treatment known improving be convenient development. levels then very protected once the leaving pathway A the inhibitors from to threatening reactants. less substantially or factor reactant is these better or beyond native translate either the alternative to their has an intravenously. a capability
data trial is are ongoing. some on N or recent patients. these our three the time fall ranges points naive I our at said, capturing points from data, more release here And nine, updates hemoglobin. treatment Now OMSXXX the as the press PNH depending in look patients, of timeline, first on for to We’ll number earlier of patients. Enrollment, since where important data on
laboratory So mean baseline for study X.X and deciliter. hemoglobin grams normal the to grams XX. The to in XX women for per as point, reference deciliter men XX.X a XX.X. is range hemoglobin per X is
XX X.X in is X.X in So at hemoglobin per mean in at and absolute deciliter, study, day increase day XX, X.X hemoglobin at day the grams absolute deciliter. mean grams is our per increase XXX
Meaning, twice patients than by Well, dose, all by had been only a with that. hemoglobin And had per deciliter or all hemoglobin day of XX% greater at more. levels level first and X following day least increase the XXX, level XX per two increase deciliter an of only grams the XX, after X achieving threshold deciliter per their have patients achieved what them by or X of grams of deciliter more. two-thirds gram day level a XX or hemoglobin of XX.X per grams patients this XX% a So hemoglobin By higher. grams achieved? doses, patients of increased
XX,XXX Hemoglobin to study. And reticulocyte and absolute least XX,XXX hemoglobin had microliter throughout from by Also a had So mean transfusion, definition, per all within ranging time patient required at had was none normal they remains none microliter. baseline treatment. have levels. time clinical at per XXX,XXX significant restored has the at receiving points, breakthrough, in the statistically to all OMSXXX from reduction counts points thrombotic well a no been a improvement all have event while
or limit Now LDH in the is that's liter, Mean from upper reduction reduction less either dose the time LDH limit in following let's mean per with XX%. is units reduction mean LDH than available the of last data. LDH normal. OMSXXX nearly patients four the XX% levels is XX, eight of than XX%. day higher X.X after the upper XXXX the at having LDH day At LDH days XXX, normal all times fold doses And LDH first of is normal. baseline baseline XX examine point the
cell LDH dosing reduction throughout of from we're statistically blood on all which two of and at and a to allow even addition market the study hemoglobin to also caused compare dose Just our results or point nine evaluate results and on is that syndrome, two of to even for in data of pathway to to the others a often increases development. plan LDH data study. other suppresses of the all blocks here alternative in available this have the study, It's have interval. and we important patients time detailed to impressive, remains inhibitors date enrolled points PNH the PNH, by in at now lowest patients like in more move OMSXXX the to dose, that this levels. This data, that favorably out aplastic significant type lowest comparison our myelodysplastic the and the red mature and anemia, destruction longer preparing that red these cancer production of cells to cells exposures the production red higher doses LDH Yet, very blood hemoglobin publicly in
these PNH appears to extremely OMSXXX, all of So challenges, despite these in patients. be well performing
patients for OMSXXX with monotherapy demonstrate receiving to then provide and therapy. response combination OMSXXX The enrolling PNH therapy switch already PNH ravulizumab a design begun. second XX then This OMSXXX hemoglobin OMSXXX providing ravulizumab weeks, with who has clinical combination trial in with patients trial is in has over a ongoing. Treatment adding
also third We treating rare or OMSXXX, evaluating disease. with have trial this X complement patients CXG, clinical a a one kidney glomerulopathy
of we medical plan PNH is inhibitor as Here to really plan of all OMSXXX though of congresses. a pathway. provide and at this data the the our effective and alternative well year, on in second clearly three to of data data half MASP-X demonstrate trials really we date highly present updates that upcoming to The
the to other and been that alternative drug already significantly Those programs be competitors much the has our PNH, met. by disorders. pathway and in who be of field. has development are across guesswork nearly data well diseases removed. that been should inhibition alternative indications which have in to given already the This our and other validated effective should confident accelerate continue identified requirement of our of those Given already We're the perform pathway OMSXXX complete and the
The steps indications team possible, that X this quickly the and is Our focused dose doses X higher multiple as trials achieving identify across next we to Phase trials. evaluate OMSXXX to are so is the aim soon optimal on committed goal. and as complete for of can to Phase initiate and
to PDEX compulsion, and in We've inhibition also craving with now and animals both blocks effective opioid, OMSXXX and in shown inhibition shown relapse published of or Turning animal substances we've program. PDEX PDEX inhibitor alcohol abuse of binge in data addiction. eating. specifically, is nicotine that across that in positive models cocaine,
current do significant the of system. depress and which a reward In to system, relapse, anti-addiction advantage agents, craving to the depress appear not over both PDEX inhibitors all do reward addition blocking
So last in development. challenging. Abuse support these Institute year on the announced of part with Last of a PDEX substance enjoyment only other OMSXXX National a animal inhibitor. making orally other continued NIDA agents human of administered use seen NIDA, In the Phase explore market Health, patient's of in a year collaborate in three the of while we quite the grant depression. craving, other reduction OMSXXX month, a National of to compliance the be million the development Omeros treatment over frankly, had a This Drug could a from to disorders. lead NIDA on our of X.X or award the development the Institutes advancing out on which all us having for limited reward and we've anti-addiction ways reached to major treatment in inhibitors and life, OMSXXX, of between cause effect or would aspects with can of general, agents and X clinical studies PDEX of the no system differentiator run evidence on
with disorder. begin use to wanted cocaine NIDA
based cocaine and effectiveness treatments from and field, specifically age in six highly disorder disorder part both academia, of in in intended X.X and the both of the placebo by than tied years system receive double to or substance XXXX expect disorder, XX awarded. XX,XXX in was million submitted epidemic people Americans, with cocaine. cocaine the or other in challenge be team and So to And of randomized is solution compulsions, The the that eating. disorder. leaders binge trillions. disorder the in others older, that from use in funding study FDA experienced the into comparing the US use blind of of X.X inhibitor our of patient estimated by PDEX the a societal is prepared to and on application. working and PDEX same no use could the overdoses. massive industry use review dopamine this approved costs and Americans of look of We There drug concurrent and Research intravenous inhibition died shows a cocaine mechanism clinical cocaine the team runs including grant XXXX, in the abuse major similar brain, addictions addiction. to adults societal a One and forward for including work, preclinical use who nicotine, our a to opioids, NIDA alcohol treatment the with well have in cocaine support our that grant addiction million substance are An and more safety to
Emory Omeros collaborators broad disorders University. PDEX with properties also intellectual at and surrounding our controls movement inhibition
patients numerous evaluated LID and opportunity. large of in LID. than is the well Amantadine those caused by LID. and treatment Parkinson's a are treated a million substantial most effective dyskinesias predictive investigators are part a with as is used from adverse XX% prescribed the induced significant We reportedly disease has developed of in extensively drug L-DOPA dyskinesias approved market OMSXXX. movements Extended evaluated have also and patients L-DOPA and a efficacy more unmet Emory at use in suffer for good Parkinson's to need have for treat is Parkinson's Only result, potential prolonged suboptimal side and treatment These L-DOPA but patient itself amantadine most treatment is living of worldwide More XX or drug by The LID as Emory highly one with a the its represents as crippling, of model. are OMSXXX or involuntary with L-DOPA. evaluating extended been release by LID, limited efficacy primate effects. model and release clinical that as
on after them received publicly have data patent filing from we We applications. all disclose recently OMSXXX and appropriate Emory will
corporate oncology estates and broad patent today's our two end There immuno are each. IO will with programs. expansive subsets therapies, of building our We cellular are namely or franchise, biologic around update platforms and we
Our follow population T-cell once signaling T-cell are therapies, tumor of is to kill platform T-cells work the effectively CAR-T based on our of GPRXXX comprised recognize and and identification tumor from of which our expand specific body's and both novel cellular these pathways, inhibited, specific cells. adoptive approaches on memory that of
to date T-cell cost could decreasing expressing our unlike and Our not administration. available efficacy CAR-T approaches, beyond rates a represents and adoptive cancer T-cell adoptive therapies. Increasing cellular patients data improve rapidity not preparation, liquid to of do currently programs T-cell modification If [multiply] by clinic, This or require both limited the therapies, our engineering both are across tumors. antigens. adoptive currently response enabling in advance solid enhancing surface and hold CAR-T for repetitive available substantially cell revolutionary potentially treatment and
molecules, our of of we more potent even binders or some body equally is work, function Based platform tumor biologic adjuvants. therapeutic to against novel broad tumors. with vaccines classes expect consisting as in combining wide the of Our antigen range on a
survival the across to generated our tumors. products date, might data effects limiting specifically, the platform the available are and from to rates be the we overcome that biologic of the again, of hematologic to tumor have have well improve vaccines, only the data acting transient. on that Here efficacy potential long currently suggest our and beneficial the solid available challenges Based vaccines the greatly
Accounting Mike our over call detailed go of discussion turn now Mike? to a through I'll more Jacobsen, to Officer, Chief our first results. quarter the financial
